Literature DB >> 16434654

Embolization of pulmonary arteriovenous malformations and decrease in prevalence of migraine.

M C Post1, V Thijs, W J Schonewille, W Budts, R J Snijder, H W M Plokker, C J J Westermann.   

Abstract

OBJECTIVE: To determine if embolization of pulmonary arteriovenous malformations (PAVMs) decreases the occurrence of migraine.
METHODS: All 105 patients with hereditary hemorrhagic telangiectasia (HHT), minimum age 16 years, who underwent an embolization of PAVM in our hospital between June 1995 and April 2004, were included in this study. A structured headache questionnaire was sent to all patients and focused on two periods: 1 year before and at least 6 months after embolization. Two independent neurologists diagnosed migraine according to the International Headache Society criteria.
RESULTS: Eighty-four patients (80%) sent back the questionnaire (mean age 47.8 +/- 15.1 years, 51 female). Median follow-up time was 48 months (first quartile: 23 months; third quartile: 66 months). The overall prevalence of migraine decreased from 45.2% before to 34.5% after embolization (p = 0.01). The prevalence of migraine with aura decreased from 33.3% before to 19.0% after embolization (p = 0.002). The severity of headache attacks decreased in patients who still had migraine (p = 0.15) or migraine with aura after embolization (p = 0.11).
CONCLUSION: Embolization of pulmonary arteriovenous malformations in patients with hereditary hemorrhagic telangiectasia seems to be related to a decrease in prevalence of migraine, suggesting that the presence of a right-to-left shunt rather than the localization of this shunt plays a causative role in the pathogenesis of migraine.

Entities:  

Mesh:

Year:  2006        PMID: 16434654     DOI: 10.1212/01.wnl.0000194257.75559.b0

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  13 in total

Review 1.  Embolisation for pulmonary arteriovenous malformation.

Authors:  Charlie C-T Hsu; Gigi Nc Kwan; Hannah Evans-Barns; Mieke L van Driel
Journal:  Cochrane Database Syst Rev       Date:  2018-01-04

Review 2.  Pulmonary arteriovenous malformations.

Authors:  Claire L Shovlin
Journal:  Am J Respir Crit Care Med       Date:  2014-12-01       Impact factor: 21.405

3.  Migraine headaches following catheter ablation for atrial fibrillation.

Authors:  Amit Noheria; John Roshan; Suraj Kapa; Komandoor Srivathsan; Douglas L Packer; Samuel J Asirvatham
Journal:  J Interv Card Electrophysiol       Date:  2010-10-19       Impact factor: 1.900

4.  Pulmonary hypertension in hereditary haemorrhagic telangiectasia.

Authors:  Veronique Mm Vorselaars; Sebastiaan Velthuis; Repke J Snijder; Jan Albert Vos; Johannes J Mager; Martijn C Post
Journal:  World J Cardiol       Date:  2015-05-26

5.  Migraine with aura and persistent foramen ovale.

Authors:  P T Wilmshurst
Journal:  Eye (Lond)       Date:  2017-12-08       Impact factor: 3.775

Review 6.  The migraine association with cardiac anomalies, cardiovascular disease, and stroke.

Authors:  Todd J Schwedt
Journal:  Neurol Clin       Date:  2009-05       Impact factor: 3.806

7.  One case of sporadic hemiplegic migraine with multiple pulmonary arteriovenous malformation.

Authors:  Mianwang He; Shengyuan Yu; Guangyi Wang
Journal:  J Headache Pain       Date:  2011-01-19       Impact factor: 7.277

Review 8.  Optimal management of hereditary hemorrhagic telangiectasia.

Authors:  Neetika Garg; Monica Khunger; Arjun Gupta; Nilay Kumar
Journal:  J Blood Med       Date:  2014-10-15

9.  Paradoxical air microembolism induces cerebral bioelectrical abnormalities and occasionally headache in patent foramen ovale patients with migraine.

Authors:  Eser Başak Sevgi; Sefik Evren Erdener; Mehmet Demirci; Mehmet Akif Topcuoglu; Turgay Dalkara
Journal:  J Am Heart Assoc       Date:  2012-12-19       Impact factor: 5.501

10.  A case of successful surgical treatment of migraine headaches in a patient with sporadic pulmonary arteriovenous malformations.

Authors:  Sang-Jun Na; Hyun Min Cho; Joon Seok Park
Journal:  J Korean Med Sci       Date:  2009-04-20       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.